JUNS JUPITER NEUROSC
-
JUPITER NEUROSC Reported Earnings
Friday, August 14, 2026 · 12:00 AM ET
JUPITER NEUROSC (JUNS) reported a loss of $5.06 per share on revenue of $0.02 million for the . .
Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia and MELAS. Jupiter Neurosciences Inc. is based in Jupiter, Florida.
Reported Earnings
($5.06)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
$0.02M
Revenue Estimate
—
Revenue Surprise
Revenue Growth—